My sense is that all these "Buyout!", "Buyout!" posts are by Big Pharma stooges. No one in their right mind would even think of selling what Brilacidin alone has to offer much less Kevetrin at this point. Your post was one of several I have seen implying Leo is old and needs to retire and so I suppose you think someone would be "doing him a favor" to buy the company out and let Leo go play in the sand and paint old people pictures or engage in some idealized retiree paradigm of worthless behavior as long as Leo "gets out of the way".
You spend decades trying to bring a great medicine to market and you get it to the point that all you have to do is manufacture it and sell it ..and then you sell the whole platform off? Why? You outsource the manufacturing ( don't have to keep up a factory or the insurance on the factory, or deal with labor or unions, etc.. ) , you outsource the advertising and the marketing and there you go. That is in fact a very good business model as opposed to keeping up multiple properties. In the trucking industry as one example, Landstar owns no trucks or trailers, leases trailers that they never own, has no maintenance facilities, and has over 10,000 owner operators maintain their own trucks to move freight that independent agents find. A very lightweight business model that rakes in the bucks. Thinking that in order to be a "proper" pharma or business at all one must have lots of real estate, equipment, lots of employees and a huge overhead/expenses is so last century if you haven't noticed. I'll take Leo with so-called 'four guys in an office' or whatever it is now over massive upkeep for lots of real estate, manufacturing, transportation and having to recruit hot looking, perfectly made up blonds, brunettes and red heads to go to doctors offices and give out free samples and make sales based on their looks and charm rather than the efficacy of the drugs.
My sense as well is that if Big Pharma wanted to buy it, they would buy it to bury it as they have whole platforms of drugs that Brilacidin seems poised to displace in the marketplace; whole budgets of advertising and lobbying and such that would be wasted should Brilacidin hit the market. I have read somewhere that there hasn't been a new class/type of anti-Biotic to hit the market since the 80's. This article is just one of many stating the stark situation and places the last new drugs since 2000:
"Every drug that enters the market costs several billion dollars, from research and development through testing. When antibiotic development proved to be the arms race described above, some of the biggest pharmaceutical firms – such as Pfizer, Roche, and Bristol-Myers – dropped like flies from antibiotic research.
The few companies that continued developing antibiotics on mostly focused on this so-called “analog discovery” – modifying the chemical structure of existing drugs just enough to bypass known resistance mechanisms, as with the beta-lactams. From a business perspective, this is safe: side effects and targets have already been classified, and approval processes will be faster. From an arms race perspective, however, this fuels antibiotic resistance by repeatedly introducing modified, but similar enough, drugs."
...Only 15 new antibiotics have been approved since 2000, compared to the 63 put to clinical use between 1980 and 2000 (Figure 1). Out of these 14 new drugs, only 4 of them represent new classes of antibiotics, targeting bacteria through novel mechanisms. Linezolid, for instance, is the first “oxazolidinone,” and it entered the market in 2000. Oxazolidinones are considered last-resort drugs to be used only when every other existing antimicrobial therapy has failed. Still, bacteria resistant to each of these new drugs have already been isolated."
"LINEZOLID is an oxazolidinone antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections."
So on the cusp of giving the world, the very real possibility of being the new penicillin as a revolution in medicine, an anti-biotic already proven to kill MRSA, already proven to have great benefits for the whole body, and very possibly to deliver the world from a pestilence, you guys keep wanting Leo to sell. I find that bizarre. Like Wow! bizarre. The sales contracts and the financing will come when the proof is there after this phase 2.
Not to put to fine a point on it, but America needs more leaders like Leo who have stood the test of ceos-of-their-armchairs running him down. You would do yourself a favor to read Teddy Roosevelt's "Citizenship in the Republic" , which Leo, by the grace of God, has exemplified.
an except:
"It is not the critic who counts; not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood; who strives valiantly; who errs, who comes short again and again, because there is no effort without error and shortcoming; but who does actually strive to do the deeds; who knows great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat."
As far as money, Leo has it made no matter what happens. Why would he continue unless he genuinely had a vision to save lives that he felt no one else could accomplish? William DeGrado is the same. They both could have retired a decade ago.
message in reply to:
"My sense is that Leo is positioning for a buy-out. If he was 35 years old with a starter drug like Brilacidin I could see him building this into a major company, but the best way to make money in the next couple of years is a buyout. If investors want to stick around for everything else you keep your shares in whatever big pharma scoops this company up."
God bless all
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating COVID-19
AI
